J
Jesse A. Jones
Researcher at University of Tennessee Health Science Center
Publications - 10
Citations - 126
Jesse A. Jones is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: Reductase & Topoisomerase. The author has an hindex of 4, co-authored 10 publications receiving 66 citations. Previous affiliations of Jesse A. Jones include Idaho State University & University of Michigan.
Papers
More filters
Journal ArticleDOI
Advances in encapsulin nanocompartment biology and engineering.
Jesse A. Jones,Tobias W. Giessen +1 more
TL;DR: Recent advances in employing engineered encapsulins across various fields are discussed, from their use as bionanoreactors to targeted delivery systems and beyond, with a special focus on the rational engineering of encapsulin systems.
Journal ArticleDOI
The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection
Ravi K. R. Marreddy,Xiaoqian Wu,Madhab Sapkota,Allan M. Prior,Jesse A. Jones,Dianqing Sun,Kirk E. Hevener,Julian G Hurdle +7 more
TL;DR: Evaluated the enoyl-acyl carrier protein (ACP) reductase II (FabK), which catalyzes the final step of bacterial fatty acid biosynthesis, and suggests that C. difficile FabK is a druggable target for discovering narrow-spectrum anti- C. Difficile drugs that treat CDI but avoid collateral damage to the gut microbiota.
Journal ArticleDOI
Recent advances in the rational design and optimization of antibacterial agents
TL;DR: This review discusses next-generation antibacterial agents developed using rational, or targeted, drug design strategies that have been designed to bypass developing bacterial resistance, improve the antibacterial spectrum of activity, and/or to optimize other properties, including physicochemical and pharmacokinetic properties.
Journal ArticleDOI
Structural characterization of Porphyromonas gingivalis enoyl‐ACP reductase II (FabK)
Kirk E. Hevener,Bernard D. Santarsiero,Hyun Lee,Jesse A. Jones,Teuta Boci,Michael E. Johnson,Shahila Mehboob +6 more
TL;DR: The determined structure has allowed insight into the structural basis for the NADPH dependence observed in PgFabK and the role of a monovalent cation that has been observed in previous studies to be stringently required for FabK activity to facilitate structure-based drug-discovery efforts towards the prevention and treatment of P. gingivalis infection.
Journal ArticleDOI
Triggered Reversible Disassembly of an Engineered Protein Nanocage
TL;DR: In this article, a peptide capable of triggering conformational change at a key structural position in the largest known encapsulin nanocompartment is introduced, and the structure of the resulting engineered nanocage is reported.